Daily Derm Times: May 19, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

Biologics and JAK inhibitors present distinct challenges in achieving optimal treatment targets for atopic dermatitis.
Elevated TNF-alpha serum levels correlate with increased severity of chronic spontaneous urticaria, suggesting potential therapeutic targets.
PHLAS, a cold plasma skin care device, enhances acne treatment and overall skin health.
JAK inhibitors are deemed safe concerning venous thromboembolic events in severe atopic dermatitis patients.
Psoriasis is linked to increased sleep disorder risks, necessitating tailored interventions for diverse populations.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Weighing In on Biologics and JAK Inhibitors for Atopic Dermatitis

Christopher Bunick, MD, PhD, discusses key differences in AD biologics and challenges in achieving optimal treatment targets.

TNF-Alpha Linked to CSU Severity

Research reveals a significant link between TNF-alpha serum levels and the severity of chronic spontaneous urticaria, suggesting new therapeutic avenues for treatment.

Julia Zimmermann PD, PhD, Demonstrates PHLAS, A New Cold Plasma Skin Care Device

Discover how Julia Zimmermann, PD, PhD's PHLAS innovates cold plasma technology for skin care, enhancing treatments for acne and skin health.

No Link Found Between JAK Inhibitor Use and Unprovoked Venous Thromboembolisms in Adults with Atopic Dermatitis

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

Psoriasis Linked to Sleep Disorders in Diverse Adults

Psoriasis significantly impacts sleep health, with diverse populations facing increased risks of sleep disorders, highlighting urgent clinical needs for tailored interventions.

Triple-Combination Acne Gel Demonstrates Long-Term Safety and Efficacy

A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.

Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD

Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!